Melatonin in Aging and Circadian Health: Beyond the Sleep Hormone

The most misunderstood supplement in America isn't really a sleep aid. It's the body's timekeeper — and what it does as we age is more specific, and more interesting, than the label on the bottle suggests.

Walk down any pharmacy aisle in the country and you'll find melatonin shelved next to the sleep aids, sold in gummies the size of a nickel, dosed as if more is better. It has become the bedtime supplement of choice for tens of millions of Americans. And almost everyone — the people taking it, and quite a few of the people recommending it — has the basic idea slightly wrong.

Melatonin is not, first and foremost, a sedative. It is a hormone your body makes in the dark, and its real job is timekeeping. Think of it less as a switch that turns sleep on and more as the conductor's downbeat that tells the whole orchestra — your brain, your liver, your blood vessels, your immune system, your gut — that night has arrived and it's time to shift into the nocturnal program. Scientists call this being a chronobiotic: a molecule that sets biological time. The master clock sits deep in the brain, in a cluster of cells called the suprachiasmatic nucleus, and melatonin is how that clock broadcasts the hour to every organ downstream. [1]

That distinction matters more as we get older, because melatonin is one of the things the body quietly stops making. By age 60, the nightly peak has typically fallen to somewhere between a half and a third of what it was in young adulthood, and the pineal gland — the pea-sized structure that produces it — tends to calcify with the decades, further muffling the signal. [1] What's striking is the company this decline keeps. It arrives alongside the familiar signatures of aging: sleep that breaks into pieces, a thinner reserve of natural antioxidants, a low simmer of chronic inflammation, and a growing mismatch between the master clock and the peripheral clocks it's supposed to be synchronizing. Whether the fading melatonin causes those changes, merely accompanies them, or feeds into a two-way loop is still being worked out. But the modern research increasingly treats melatonin not as a mere sleeping pill but as a systems-level regulator with fingerprints on cardiovascular, brain, and metabolic aging. [1]

For anyone carrying a heavy cognitive load through a life of time-zone hopping, late-night screens, and irregular sleep windows — which describes a great many high-functioning adults — this reframes the question. The interesting issue was never whether melatonin trims a few minutes off the time it takes to fall asleep. It's whether restoring the fidelity of the body's timing signal can measurably bend the longer arcs of heart, brain, and metabolic health. That's the question worth answering honestly.

Where the signal comes from, and why the bottle rarely matches the body

Your body builds melatonin from tryptophan (the same amino acid blamed, unfairly, for Thanksgiving drowsiness), converting it first to serotonin and then, in the pineal gland, to melatonin itself. Production is governed almost entirely by darkness. Special light-sensing cells in the retina report the arrival of light to the brain's clock, which in turn tells the pineal gland to hold off. Blue light — the short-wavelength glow that pours out of phones, laptops, and LED bulbs — is the most potent suppressor of all, which is precisely why a bright screen at 11 p.m. is chemically at odds with sleep. [2]

Left alone, the nightly rise follows a clean curve: it begins climbing two to three hours before your usual bedtime, crests somewhere between 2 and 4 in the morning, and tapers toward dawn. Aging flattens that curve from every direction at once — the rise comes later, the peak comes lower, and the whole arc loses its crispness — and it does so on its own, with or without anything you swallow. [2]

Here's where the retail version parts ways with the biological one. Swallowed melatonin is absorbed erratically; only a small and variable fraction, somewhere between 3 and 15 percent, actually survives the first pass through the liver, where an enzyme called CYP1A2 breaks most of it down. It rises fast — peak blood levels in twenty minutes to an hour — and clears fast, with a half-life of roughly 35 to 50 minutes, far shorter than a typical prescription sleep drug. That short life span is the whole ballgame. A small, physiologic dose — the 0.3 to 0.5 milligrams that roughly mirrors what your body would make on its own — comes and goes like the real thing. The 3-to-10-milligram doses that dominate store shelves push blood levels ten to twenty times above the natural peak and, in some people, keep the receptors bathed well into the next morning. This is the quiet mechanism behind next-day grogginess. There's also a prolonged-release formulation, engineered to trickle out over the night and imitate the natural secretion curve; it's the version most European insomnia trials have relied on. And individual chemistry matters: genetic differences in that CYP1A2 enzyme, along with smoking, certain antidepressants, and oral contraceptives, can all meaningfully change how fast a person clears the hormone.

What melatonin is actually doing in the body

Keeping time. Melatonin works mainly through two receptors, known as MT1 and MT2, clustered densely in the brain's master clock. Switching on MT1 quiets the clock's electrical chatter and nudges the brain toward sleepiness; switching on MT2 does something subtler and arguably more important — it shifts the clock, moving your entire internal day earlier or later. This second effect is the basis for melatonin's most legitimate use, resetting time itself, which is a different thing from knocking you out. As we age and both our sensitivity to light and our own melatonin output fade, this timing signal weakens — which helps explain the early-to-bed, early-to-wake drift, the fragmented nights, and the daytime drowsiness so common in later life. [2]

Protecting the cell's engines. Entirely apart from those receptors, melatonin and the compounds it breaks down into act as direct antioxidants — they neutralize the reactive molecules that damage cells — and they prompt the body to ramp up its own defensive enzymes with names like superoxide dismutase and glutathione peroxidase. More intriguing still, melatonin concentrates inside mitochondria, the tiny power plants in every cell, reportedly at levels higher than in the bloodstream. There it steadies energy production and limits the leakage of damaging free radicals. Since failing mitochondria are one of the recognized hallmarks of aging, a molecule that congregates exactly where the trouble starts is worth paying attention to. [3]

Housekeeping in the brain. In laboratory work, melatonin appears to tune up autophagy — the cell's system for clearing out and recycling its own damaged and misfolded proteins, including the amyloid-beta and tau implicated in Alzheimer's disease. [3] It also dampens a central inflammatory pathway (NF-κB) and supports the brain's glymphatic system, the overnight rinse cycle that flushes metabolic waste while you sleep and that depends on sleep to work. String those together and you get a plausible line from better circadian signaling to slower neurodegeneration — though it's essential to be clear that this chain still lives largely in the laboratory, not yet in patients.

Tending the blood vessels. Melatonin receptors also sit on the lining of blood vessels and on vascular muscle, where the hormone has been shown to lower oxidative stress, improve the availability of nitric oxide (the molecule that lets vessels relax), and modestly correct a specific problem called non-dipping — the failure of blood pressure to fall as it should overnight, a pattern independently tied to cardiovascular risk as we age. [8]

What the human trials actually show

Mechanisms are seductive, but the honest measure is what happens in real people. The picture there is genuinely encouraging in a couple of places and genuinely underwhelming in others — and the difference is the whole point.

It helps older sleepers, measured objectively. In a tightly controlled crossover study, researchers gave 24 healthy older adults (average age 64) either a low dose (0.3 mg), a high dose (5 mg), or a placebo, and recorded their sleep in a lab with electrodes rather than trusting self-reports. The 5 mg dose meaningfully improved sleep efficiency — the share of time in bed actually spent asleep — during both the biological day and night, mostly by lengthening the light, restorative stages of sleep and trimming the awakenings. The low dose helped, too, but in a narrower, daytime-only way. This is one of the few rigorous trials to isolate melatonin's sleep effect specifically in older people using hard measurement instead of a morning questionnaire. [4]

It is not, however, a cure-all for adult insomnia. A systematic review pooling 24 randomized trials delivered the sobering counterweight. In adults with ordinary, standalone insomnia — no other condition driving it — melatonin on its own did not reliably improve how fast they fell asleep, how long they slept, or how efficiently. It performed more consistently when the insomnia rode alongside another problem, and in children. [5] This deserves to be said plainly, because it runs against the marketing: for the otherwise-healthy, middle-aged adult who simply can't sleep, melatonin is not a dependable fix, and anyone promising otherwise is overselling.

The formulation you choose is a real variable. A larger review — 22 studies and nearly 4,900 participants — compared prolonged-release melatonin and a prescription cousin called ramelteon against placebo. Zoom in on the subgroup aged 55 and older and the prolonged-release version produced a large improvement in objectively measured sleep efficiency (a gain of about 3 percentage points, a statistically robust result), notably stronger than the modest effect across the whole population. [6] That age-specific signal maps almost perfectly onto the readers of this publication, and it carries a practical lesson: the slow-release form, not the fast-hitting one that fills the retail shelves, is the one with the evidence behind it in older adults.

In dementia, expectations have to come down. A Cochrane review — the gold standard of evidence synthesis — looked at sleep treatments for people with dementia, including five melatonin trials totaling 222 patients. At doses up to 10 mg, melatonin showed only low-certainty evidence of little or no benefit for total nighttime sleep, efficiency, or nighttime waking in Alzheimer's-related sleep disturbance. It was reassuringly safe — no serious side effects in any melatonin arm — but other agents (trazodone, and a newer class called orexin antagonists) outperformed it in this group. [7] The cognitively impaired brain, in other words, responds differently from the healthy older brain, and that difference should shape anyone's hopes.

And then, a real vascular signal. Perhaps the most provocative human result has nothing to do with sleep at all. In a year-long randomized study of people with high blood pressure, a low dose of melatonin — just 1 mg a day, added to their usual care — significantly improved arterial stiffness, a hard, measurable marker of vascular aging that tracks with heart risk. The improvement moved in step with a measurable drop in oxidative stress. (A separate measure of blood-vessel function trended in the right direction but didn't reach statistical significance, and the study was small — 23 people.) Still, this is one of the rare human trials tying low-dose melatonin to a genuine aging biomarker rather than to how someone rated their night's sleep. [8]

On Alzheimer's, promise without proof. A 2024 review pulled together the biology and the clinical trials of melatonin across the many pathways it touches in Alzheimer's disease. The verdict was candid: the cognitive benefits in trials have been modest and inconsistent, and the most reproducible effect is better sleep-wake regulation, not a slowing of the disease itself. The authors flagged the field's real weakness — trials that never agreed on dose, formulation, or duration — which is exactly why no one can yet claim melatonin protects the aging brain. [9]

Who this is actually for

Taken together, the evidence points to melatonin being genuinely useful, but for narrower and more specific reasons than its reputation implies. It is on firmest ground for two things: resetting a clock that's out of sync — jet lag, shift work, a sleep schedule that has drifted too early or too late — and improving sleep efficiency in adults 55 and up, where the numbers are meaningfully better than in younger people with plain insomnia. [4][6] Outside those lanes — ordinary adult insomnia, and dementia-related sleep trouble — the case is considerably weaker, and it shouldn't be sold as a universal solution. [5][7]

If you see yourself in one of the following, it's worth a conversation with your physician:

• The frequent traveler or rotating-schedule professional, for whom melatonin is best used as a timing tool — taken at a strategic hour to shift the clock toward a new time zone — rather than as a nightly sedative.

• The adult 55 or older with genuinely fragmented sleep, where the slow-release formulations have the strongest track record.

• The person managing high blood pressure and elevated oxidative stress, for whom low-dose melatonin may serve as an adjunct — an addition to, never a replacement for, standard treatment.

• The person with mild cognitive complaints and a scrambled sleep-wake cycle, where restoring the timing signal may offer some secondary benefit — with the honest caveat that this evidence is still preliminary.

• 
  

What the research actually used — a note on dose

Because dose is where melatonin most often goes wrong, it's worth spelling out what the studies actually tested. These are not prescriptions — they are the figures a well-informed reader should bring to their own doctor.

For resetting the clock (jet lag, shift work), the pharmacology favors small, physiologic doses — roughly 0.3 to 0.5 mg — timed several hours before the target bedtime rather than at the moment your head hits the pillow. Bigger is not better here; low doses more faithfully imitate what the body makes.

For sleep in older adults, the trials showing the strongest objective benefit used 2 to 5 mg, and prolonged-release was the formulation of choice, taken 30 to 60 minutes before bed. [4][6] Notably, these were run as defined trials, not open-ended habits: a sensible course is a matter of weeks with reassessment, not an indefinite nightly ritual, since the long-term data thin out past the three-month mark.

For the vascular signal, the hypertension study used 1 mg a day over a full year, again as an add-on to standard blood-pressure treatment, not a stand-in for it. [8]

Two through-lines run beneath all of this. First, favor the prolonged-release form over the supraphysiologic quick-release doses that dominate the retail market. Second, match the dose to the goal rather than defaulting to whatever the gummy happens to contain — the right amount for shifting a clock is not the right amount for holding sleep in a 65-year-old.

Safety: reassuring, with a few genuine cautions

Melatonin's safety record across these trials is favorable; no serious adverse events were reported even at doses up to 10 mg. [7] The common complaints are mild — next-morning grogginess (most likely with those big quick-release doses), headache, dizziness, and unusually vivid dreams. And because most American products are dosed at 3 to 10 mg, well above what the body would ever make, lingering next-day sedation is an underappreciated, practical concern — particularly for older adults, in whom a groggy morning can mean a fall.

A few situations call for real caution and a physician's input before starting:

• Autoimmune conditions. Melatonin nudges the immune system, so it warrants care in anyone on immune-suppressing therapy.

• Seizure disorders. There's a theoretical concern about seizure threshold; the evidence is mixed and unsettled.

• Pregnancy and breastfeeding. Safety data are insufficient; not recommended outside a clinical trial.

• Untreated depression or bipolar disorder. Anything that acts on the body's clock can, in theory, influence mood cycling — use only with psychiatric guidance.

It also interacts with a number of medications. Certain antidepressants (fluvoxamine and other CYP1A2 inhibitors) can dramatically raise melatonin levels and call for a lower dose. Melatonin may have mild blood-thinning activity, worth monitoring for anyone on warfarin or the newer anticoagulants. It can add to the effect of blood-pressure medications, so combinations deserve watching, especially at the start. It compounds the sedation of other sleep aids and alcohol. And it may, in theory, work against immune-suppressing drugs.

One more thing, and it's not a footnote: in the United States, melatonin is sold as an unregulated dietary supplement. Independent testing has repeatedly found that what's in the bottle can differ substantially from what's on the label. Sourcing from third-party-tested, pharmaceutical-grade products is not fussiness — it's the difference between taking a known quantity and taking a guess.

The bottom line

Melatonin's real value in longevity-minded medicine is genuine but more precise than the drugstore version of the story. Its strongest evidence supports two distinct uses: low-dose, well-timed clock resetting for circadian misalignment, and prolonged-release dosing of 2 to 5 mg for better sleep efficiency in adults 55 and older. [4][6] Beyond those — in everyday adult insomnia and dementia-related sleep problems — the evidence is thinner, and honesty requires saying so. [5][7]

The more compelling long-range story is the one that has little to do with sleep. Melatonin behaves as a mitochondria-targeting antioxidant, a housekeeping signal for cells, and a molecule that speaks directly to blood vessels. The year-long hypertension trial offers preliminary but real human evidence that low-dose melatonin can improve arterial stiffness — a hard marker of how the cardiovascular system ages — independent of anything it does for sleep. [8] The brain-protection research, spanning waste clearance and the overnight glymphatic rinse, remains genuinely compelling at the level of mechanism, but it has not yet produced a disease-slowing result in Alzheimer's trials. [3][9] That gap — between what should work and what has been shown to work — is the line to keep in view: melatonin is a physiologically grounded circadian and antioxidant tool with an excellent safety margin, not a proven defense against neurodegeneration.

The practical takeaways are refreshingly simple. Choose slow-release over the megadose quick-release that fills the shelves. Match the dose to what you're actually trying to accomplish. Treat it as a defined course to be reassessed, not an automatic lifelong habit. And before starting a higher dose later in life, have your physician check for interacting medications and fall risk. Used that way, melatonin earns a legitimate, evidence-backed place in a thoughtful longevity plan — a long way from its cartoon reputation as a bedside gummy.

References

[1] Jagota A, Khan ZA, Sharma SA, Priyanka. Multifaceted dynamics of circadian timing system influence aging and longevity. Biogerontology. 2025;26(5):184. PMID: 41015586. https://pubmed.ncbi.nlm.nih.gov/41015586/

[2] Chellappa SL, Bromundt V, Frey S, Cajochen C. Age-related neuroendocrine and alerting responses to light. GeroScience. 2021;43(4):1767-1781. PMID: 33638088. https://pubmed.ncbi.nlm.nih.gov/33638088/

[3] Luo F, Sandhu AF, Rungratanawanich W, et al. Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. Int J Mol Sci. 2020;21(19):7174. PMID: 32998479. https://pubmed.ncbi.nlm.nih.gov/32998479/

[4] Duffy JF, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. J Pineal Res. 2022;73(1):e12801. PMID: 35436355. https://pubmed.ncbi.nlm.nih.gov/35436355/

[5] Choi K, Lee YJ, Park S, Je NK, Suh HS. Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. Sleep Med Rev. 2022;66:101692. PMID: 36179487. https://pubmed.ncbi.nlm.nih.gov/36179487/

[6] Maruani J, Reynaud E, Chambe J, Palagini L, Bourgin P, Geoffroy PA. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis. J Sleep Res.2023;32(6):e13939. PMID: 37434463. https://pubmed.ncbi.nlm.nih.gov/37434463/

[7] McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev.2020;11(11):CD009178. PMID: 33189083. https://pubmed.ncbi.nlm.nih.gov/33189083/

[8] Franco C, et al. Essential Hypertension and Oxidative Stress: Novel Future Perspectives. Int J Mol Sci.2022;23(22):14489. PMID: 36430967. https://pubmed.ncbi.nlm.nih.gov/36430967/

[9] Steinbach MJ, Denburg NL. Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials. J Alzheimers Dis. 2024;101(s1):S193-S204. PMID: 39422936. https://pubmed.ncbi.nlm.nih.gov/39422936/

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented is intended to support informed conversations with your licensed healthcare provider. Consult a qualified physician before initiating any new health protocol, supplement regimen, or medical intervention. Individual results vary.